Trial
NCT01625260
A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Altor BioScience
Collaborators
James and Esther King Biomedical Research Program
Condition
Non-muscle Invasive Bladder Cancer
Intervention
ALT-801
Why stopped
The study was terminated early due to low enrollment.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-07-19